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Abstract 
Background 
Belatacept, an inhibitor of the CD28-CD80/86 co-stimulatory pathway, allows for 
calcineurin-inhibitor free immunosuppressive therapy in kidney transplantation but is associated 
with a higher acute rejection risk than ciclosporin. Thus, no biomarker for belatacept-resistant 
rejection has been validated. In this randomized controlled trial, acute rejection-rate was 
compared between belatacept- and tacrolimus-treated patients and immunological biomarkers for 
acute rejection were investigated. 
Methods 
Forty kidney-transplant recipients were 1:1 randomized to belatacept or tacrolimus 
combined with basiliximab, mycophenolate mofetil and prednisolone. The 1-year incidence of 
biopsy-proven acute rejection was monitored. Potential biomarkers, namely CD8
+
CD28
-
, 
CD4
+
CD57
+
PD1
-
 and CD8
+
CD28
++
 EMRA T cells were measured pre and posttransplantation 
and correlated to rejection. Pharmacodynamic monitoring of belatacept was performed by 
measuring free CD86 on monocytes.  
Results 
The rejection incidence was higher in belatacept-treated than tacrolimus-treated patients: 
55% vs. 10%; p = 0.006. All 3 graft losses, due to rejection, occurred in the belatacept group. 
Although 4 of 5 belatacept-treated patients with >35 cells CD8
+
CD28
++
 EMRA T cells/µL 
rejected, median pretransplant values of the biomarkers did not differ between belatacept-treated 
rejectors and nonrejectors. In univariable Cox regressions, the studied cell subsets were not 
associated with rejection-risk. CD86 molecules on circulating monocytes in belatacept-treated 
patients were saturated at all time points.  
Conclusions 
Belatacept-based immunosuppressive therapy resulted in higher and more severe acute 
rejection compared to tacrolimus-based therapy. This trial did not identify cellular biomarkers 
predictive of rejection. In addition, the CD28-CD80/86 co-stimulatory pathway appeared to be 
sufficiently blocked by belatacept and did not predict rejection. 
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Introduction 
 Belatacept, an inhibitor of the CD28-CD80/86 co-stimulatory pathway, has the potential 
to improve long-term outcomes of kidney transplantation.
1-5
Seven year follow-up of the 
BENEFIT study demonstrated a higher patient and graft survival, as well as better graft function 
in patients who were treated with belatacept as compared to ciclosporin.
1
Nonetheless, the higher 
incidence and severity grade of acute rejection (AR) that have been observed among belatacept-
treated patients remain a concern.
6-9
 Up until now, belatacept has not been compared head-to-
head with tacrolimus in randomized-controlled trials (RCTs) in kidney transplantation without 
the use of lymphocyte-depleting therapy.
10-12
 Observations made in uncontrolled studies suggest 
that the performance of belatacept in terms of preventing acute rejection as compared with 
tacrolimus may be inferior.
13, 14 
 
Identification of patients’ pretransplantation who will develop AR during belatacept 
treatment would greatly help to personalize immunosuppressive therapy and maximize the 
potential of the drug. Experimental studies in rhesus macaques and ex vivo studies using human 
lymphocytes have demonstrated that antigen-experienced, cytotoxic CD28
-
CD8
+
 T cells are not 
dependent on co-stimulatory signaling via CD80/86 and are therefore less susceptible to the 
immunosuppressive effects of belatacept.
15-17
 Recently, Espinosa and colleagues suggested that 
patients with a high frequency of cytotoxic CD57
+
PD1
-
CD4
+
 T cells were at increased risk of 
AR during belatacept treatment.
18
 A preliminary study in nonhuman primates suggested another 
biomarker for AR under belatacept, namely CD28
++
 end-stage differentiated (EMRA) CD8
+
 T 
cells that rapidly downregulate CD28 after kidney transplantation.
19
 Biomarkers such as these 
may help in risk stratification and a more rational use of belatacept, but require prospective 
validation.  
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Alternatively, therapeutic drug monitoring (TDM) of belatacept therapy may improve 
outcomes. Because serum belatacept concentrations tend to vary little between individual 
patients, pharmacokinetic TDM is currently not recommended.
5, 20
 However, pharmacodynamic 
TDM of belatacept is feasible. Ex vivo flowcytometric measurement of CD86 occupancy on 
monocytes by belatacept reflects effector T cell function,
21
 demonstrating the potential of TDM 
to improve outcomes of belatacept therapy. However, no data from prospective clinical trials is 
available to provide guidance in this respect.  
 
Here, the results of a RCT are reported in which forty patients were randomized to 
receive either belatacept- or tacrolimus-based immunosuppressive therapy after de novo kidney 
transplantation. The primary aims of this RCT were to compare the AR rate between belatacept 
and tacrolimus-treated patients and to identify biomarkers that were predictive of AR.  
 
Materials and Methods 
Refer to Supplemental Digital Content (SDC, http://links.lww.com/TP/B427), Materials 
and Methods for additional and detailed information. 
Study design 
This was an investigator-initiated, prospective, randomized-controlled, parallel group, 
open-label, single-center, clinical trial. Adult patients (≥18 years) who were scheduled to receive 
a single-organ, blood group AB0-compatible kidney from a living donor at the Erasmus MC, 
Rotterdam, the Netherlands, were eligible for participation. Historical and current cross-match-
dependent cytotoxicity tests were negative. Table 1 lists the inclusion and exclusion criteria in 
detail. The study was approved by the institutional review board of the Erasmus MC (Medical 
Ethical Review Board number 2012-421) and was registered in the Dutch national trial registry 
(http://www.trialregister.nl/trialreg/index.asp; number NTR4242, registered October 2013). 
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
7 
 
Written informed consent was obtained from all patients before inclusion and randomization. 
The study was carried out in compliance with the Good Clinical Practice guidelines 
(http://apps.who.int/prequal/info_general/documents/gcp/gcp1.pdf) and the Declaration of 
Istanbul.
22 
 
Randomization procedure and intervention 
Enrolled patients were randomly assigned on a 1:1 basis by 1 of the coordinating 
investigators (G.N.G. or D.A.H.) to either receive tacrolimus (Prograf®; Astellas Pharma, 
Leiden, the Netherlands) or belatacept (Nulojix®; Bristol Myers-Squibb, New York City, NY). 
Randomization was performed by use of 40 sealed, opaque, sequentially numbered envelopes 
containing treatment allocation. The random allocation sequence was generated by an 
independent biostatistician by use of a random number generator. Before the start of the study, it 
was determined that 20 patients would be allocated to each treatment arm. Data were collected 
and monitored by the coordinating investigators in a hospital-based electronic study database. 
 
Tacrolimus was dosed based on bodyweight (a dose of 0.2 mg/kg/day in 2 equally 
divided doses, rounded off to the nearest 0.5 mg) per the package insert 
(https://www.astellas.us/docs/prograf.pdf). Thereafter, the tacrolimus dose was adjusted based on 
whole-blood predose concentrations. The tacrolimus target predose concentrations were as 
follows: 10-15 ng/mL (weeks 1 and 2), 8-12 ng/mL (weeks 3 and 4) and 5-10 ng/mL from week 
5 onwards. Belatacept was dosed per the Less-Intensive (LI) regimen as described previously.
6, 7
 
Belatacept was administered intravenously in a dose of 10 mg/kg on the day of transplantation 
(day 0) and on days 4, 15, 30, 60 and 90 after transplantation. Thereafter, the dose was reduced 
to 5 mg/kg and given as monthly infusions up until month 12 after transplantation (end of study). 
Additional treatment is discussed in the SDC, http://links.lww.com/TP/B427. 
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Safety 
Refer to SDC, http://links.lww.com/TP/B427 Material and Methods for data collection on 
(serious) adverse events. 
Primary end points 
 The overall aim of this trial was to determine the effect of belatacept and tacrolimus-
based immunosuppressive regimens on alloreactivity after kidney transplantation. The primary 
endpoint of the study presented here was the incidence of biopsy-proven acute rejection (BPAR) 
within the first year after transplantation. BPAR-rates were compared between belatacept- and 
tacrolimus-treated patients. We postulated that the incidence of BPAR would be higher among 
belatacept-treated patients
7
 and that BPAR-biomarkers could be identified. All kidney transplant 
biopsies were obtained for cause and no protocol biopsies were obtained. Refer to SDC, 
http://links.lww.com/TP/B427 Materials and Methods for BPAR scoring system.  
 
Pretransplant circulating frequencies of CD8
+
CD28
-
, CD4
+
CD57
+
PD1
-
 and end-stage 
terminally differentiated memory (EMRA) CD8
+
CD28
++
 T cells, as well as their intracellular 
expression of a Granzyme B (GrB: an important cytotoxic protease during acute rejection) were 
measured as immunological primary end points.
19, 23, 24
 These cell subsets were also measured 
posttransplantation, during acute rejection before additional anti-rejection therapy was given, or 
3 months after transplantation in nonrejecting belatacept-treated patients. Free CD86 expression 
on circulating CD14
+
 monocytes were determined pretransplantation as a predictor for rejection; 
and before every dose of belatacept administered after transplantation as a pharmacodynamic 
drug monitoring tool. A for belatacept competitive monoclonal antibody was used (clone 
HA5.2B7, Beckman Coulter, Brea, CA). In patients who rejected, the free CD86 expression was 
also assessed before additional anti-rejection therapy was given. Refer to SDC, 
http://links.lww.com/TP/B427Material and Methods for detailed information about our 
laboratory studies, including detection methods for DSA.  
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No formal statistical power calculation for the present study was performed, because 1) 
when the study was designed, it was unclear what the difference would be between belatacept 
and tacrolimus-treated patients in terms of BPAR, as only data from the BENEFIT and 
BENEFIT-EXT, in which the comparator was ciclosporin, were available at the time;
6, 7
 2) there 
were no published data available regarding the studied biomarkers and their association with 
BPAR that could serve for such a power calculation; and 3) because of financial constraints, we 
chose to conduct the present randomized controlled clinical trial with a limited number of 
patients in both arms.
25
 In our view, the present trial should therefore be regarded as a pilot 
study. It may serve as the basis for a larger study by providing the data needed to perform a 
statistical power calculation.  
 
Statistical analyses 
Additional information is depicted in SDC, http://links.lww.com/TP/B427 Materials and 
Methods. Percentages and counts are given for categorical variables, and medians plus ranges for 
continuous variables, unless otherwise specified. Continuous variables were compared between 
the belatacept and the tacrolimus group or between belatacept-treated rejectors and nonrejectors 
using the Mann-Whitney U test, and categorical variables using the Fisher’s exact test. Patient 
and death-censored graft survival, as well as death-censored BPAR-free survival were compared 
between the belatacept and tacrolimus group using the log-rank test. All included patients were 
analyzed per the intention-to-treat principle.  
 
To determine if high numbers of cytotoxic CD4
+
CD57
+
PD-1
+
, CD8
+
CD28
-
, or 
CD8
+
CD28
++
 EMRA T cells, as well as CD86 molecules/monocyte were risk factors for BPAR, 
univariable Cox regression analyses were performed with death-censored BPAR-free survival as 
the dependent variable. Independent variables included the cell types after log transformation (to 
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ensure approximately normal distribution of these variables), treatment arm, age, gender, 
ethnicity, HLA mismatches, HLA-DR mismatches, highest PRA, and cytomegalovirus (CMV) 
serostatus. Independent variables with a p<0.10 in the univariable analyses were intended to be 
included in a multivariable Cox regression analysis to predict BPAR.  
 
Repeated measurements of CD86 occupancy on monocytes over time were compared 
between the study groups using a linear mixed model. To ensure a normal distribution of the 
model residuals, the dependent variable in the model was log transformed. Predictors were the 
values of CD86 molecules/monocyte pretransplantation, time point after transplantation (coded 
as categorical variable), treatment arm (belatacept or tacrolimus) and an interaction effect of time 
point and treatment arm to account for different trends over time between groups. The dependent 
variable was the value of CD86 molecules/monocyte after transplantation at a given time point. 
A random intercept was included in the linear mixed model to account for the within-subject 
correlations. 
 
All tests were 2-tailed and statistical significance was defined as a p value <0.05. 
Bonferroni’s correction for multiple testing was applied when necessary.26 Statistical analyses 
were performed using IBM SPSS version 21 (SPSS Inc., Chicago, IL) 
 
Results 
Patients 
Between October 1
st
, 2013 (first patient, first visit) and February 26
th
, 2015 (last patient, 
first visit) 280 patients were screened, of whom 88 were eligible for participation (Figure 1). 
Forty-eight patients did not wish to participate. Major reasons were fear of acute rejection and 
inconvenience of the monthly belatacept infusions.Forty patients were randomized and included 
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in the intention-to-treat analysis. The baseline characteristics of these patients are described in 
Table 2. Seventeen (85%) patients in the belatacept and 19 (95%) in the tacrolimus group 
completed the 1-year follow-up period (last patient, last visit occurred on February 19
th
, 2016).  
 
Patient and graft survival 
Patient survival was 95% in the tacrolimus group and 100% in the belatacept group (p = 
0.32). One patient, randomized to the tacrolimus group, died 294 days after transplantation 
because of traumatic head injury. Three graft losses, all in the belatacept group, occurred on days 
12, 59 and 161 after transplantation, resulting in a 1-year death-censored graft-survival of 85% in 
the belatacept group vs. 100% in the tacrolimus group (p = 0.08). All 3 graft losses were the 
result of glucocorticoid-resistant acute rejection (Banff type IIB in 2 cases and type III in the 
third patient
23
). 
 
Biopsy-proven acute rejection 
In total, 29 for cause biopsies were performed in the belatacept group and 10 in the 
tacrolimus group in 14 and 6 patients, respectively, p = 0.015. The incidence of BPAR was 
higher among the belatacept-treated patients than in the tacrolimus-treated patients: n = 11 (55%) 
vs. n = 2 (10%), respectively; p = 0.006 (Table 3). The death-censored BPAR-free survival was 
significantly lower in the belatacept-treated patients than in the tacrolimus-treated patients, (p = 
0.002; Figure 2). Median time to rejection of patients who experienced AR was 56 (3–120) days 
in the belatacept group and 81 (10–152) days in the tacrolimus group. BPAR was of a more 
severe histological grade in the belatacept than in the tacrolimus group (p = 0.003; Table 3).  
 
A detailed overview of the clinical course of the individual patients is depicted in Figure 
3. In the belatacept group, n = 10 patients (50%) were treated for BPAR with pulse 
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methylprednisolone therapy. Six patients (30%) received additional treatment with alemtuzumab, 
which is the preferred T cell depleting antibody in our center.
27
 In retrospect, and after revision 
by the second pathologist, 1 more patient in the belatacept group (case no. 13) was diagnosed as 
suffering from rejection but he was not treated with additional anti-rejection therapy. This patient 
had a so-called isolated v-lesion and despite not treating him, his graft function has remained 
excellent to the present day. After exclusion of this case, the BPAR rate was still significantly 
higher in the belatacept group than in the tacrolimus group. Nine patients (45%), all suffering 
from BPAR, were converted from belatacept to tacrolimus.  
 
In the tacrolimus group, n = 2 patients were treated for BPAR: in 1 case with 
methylprednisolone pulse therapy only, in the other, additional treatment with alemtuzumab was 
given. Five patients (2 in the belatacept and 3 in the tacrolimus arm) received 
methylprednisolone for suspected rejection (For details see Figure 3 legend).  
 
Safety 
 In total, 205 AEs occurred in the belatacept group (mean 10.3 per patient) and 238 in the 
tacrolimus group (mean 11.9 per patient); p = 0.41 (Table S1, SDC, 
http://links.lww.com/TP/B427). Of these, 22 and 35, respectively, were judged to be serious 
(means per patient 1.1 and 1.8, respectively; p = 0.15), excluding BPAR, graft loss, and death.  
 
 eGFR, excluding graft losses, was not different between belatacept-treated and 
tacrolimus-treated patients 12 months after transplantation (Table S2, SDC, 
http://links.lww.com/TP/B427): 54 (28–89) and 50 (33–84) mL/min per 1.73m2, respectively; p 
= 0.57. Median protein/creatinine ratio was 13.2 (5.7–343.8) mg/mmol in the belatacept group 
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and 9.0 (5.3–43.5) mg/mmol in the tacrolimus group; p = 0.44. Additional routine measurements 
are depicted in Table S2, SDC, http://links.lww.com/TP/B427.  
 
 For the on-therapy analysis on month 12; graft function before, during and after BPAR in 
the belatacept group; the incidence of DSA and non-DSA; and pharmacokinetic drug monitoring, 
refer to SDC, Results and Tables S3-5, SDC, http://links.lww.com/TP/B427.  
 
Immunological primary end-points (biomarkers) 
Three potential biomarkers for (belatacept-resistant) rejection were measured 
pretransplantation, namely CD8
+
CD28
-
 T cells, CD4
+
CD57
+ 
PD1
-
 T cells, and CD8
+
CD28
++
 
EMRA T cells. There were no significant differences in the numbers or percentages of these cells 
at baseline between the tacrolimus and belatacept groups (Table 4). The limited number of 
patients experiencing BPAR in the tacrolimus group (n = 2) precluded a meaningful statistical 
comparison between rejectors and nonrejectors in this group. Gating strategies, pretransplant 
numbers and percentages of the above-mentioned cell subsets are depicted for future rejectors 
and nonrejectors in the belatacept group (see Table S6, SDC, http://links.lww.com/TP/B427; 
Figure 4), and no statistically significant differences were observed. Intracellular Granzyme B 
(GrB) expression was measured in the cell subsets (Figure 4A). Next, we analyzed whether high 
numbers or proportions of these cell types increased BPAR risk within the first 12 after 
transplantation by conducting univariable Cox regression analyses (Table 5): 
 
1) CD8+CD28- T cells 
CD8
+
CD28
-
 T cells are mostly effector-memory cytotoxic T cells that produce large amounts 
of proinflammatory cytokines,
15-17
 and are not susceptible to co-stimulation blockade by 
belatacept. Almost 70% (31–89%) of CD8+CD28- T cells produced GrB. Higher numbers and 
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proportions of pretransplant CD8
+
CD28
-
 T cells (irrespective of their intra-cellular GrB 
expression) did not significantly increase BPAR risk in the first 12 months after transplantation 
(Hazard Ratio [HR] 1.06; 95%-CI 0.61 to1.83 and HR 1.05; 95%-CI 0.50 to 2.20, respectively; 
Table 5).  
 
2) CD4+CD57+PD1- T cells  
Next, pretransplant CD4
+
CD57
+
PD1
-
 T cells were compared between rejecting and 
nonrejecting belatacept-treated patients. These cells were recently described as being cytolytic, 
CD28
-
, and to be associated with belatacept-resistant rejection.
18
 The proportion of pretransplant 
CD4
+
CD57
+
PD1
-
 T cells was low (<2% of the CD4
+
 T cell population in most patients). 
Approximately 24% (1–74%) of these cells were GrB positive. Neither the absolute number nor 
the proportion of these cell predicted BPAR (HR 0.89; 95%-CI 0.58 to 1.27, and HR 0.90; 95%-
CI 0.59 to 1.38, respectively; Table 5).  
 
3) CD8+CD28++ EMRA T cells 
Finally, CD8
+
CD28
++
 EMRA T cells were analyzed as high numbers of these cells predicted 
belatacept-resistant rejection in primates.
19
 It was postulated that these cells rapidly down-
regulate their surface CD28 expression after transplantation, making them resistant to co-
stimulatory blockade.
19
 Circa 3% (0–3%) of these cells expressed intracellular GrB. The absolute 
numbers or proportions of pretransplant CD28
++
 cells within the CD8
+
 EMRA T cell population 
did not increase BPAR risk (HR 0.86; 95%-CI 0.58 to 1.27, and HR 1.23; 95%-CI 0.64 to 2.33, 
respectively; Table 5) Interestingly, from the 5 patients with >35 CD8
+
CD28
++
 EMRA T 
cells/µL, 4 were rejectors and only 1 was a nonrejector (Figure 4B). In the tacrolimus group the 
n=2 rejectors had <10 CD8
+
CD28
++
 EMRA T cells/µL pretransplantation.  
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The above-mentioned cell surface biomarkers were also measured in belatacept-treated 
patients during acute rejection and before additional anti-rejection therapy was given, and were 
compared with the month 3 samples from patients who remained rejection-free (Figure S1, SDC, 
http://links.lww.com/TP/B427). No statistically significant differences were observed between 
rejecting and nonrejecting belatacept-treated patients. 
 
The only significant risk factor for rejection in this study population was the use of a 
belatacept-based immunosuppressive regimen (HR 7.2; 95%-CI 1.6 to 32.6; p = 0.01) compared 
to tacrolimus-based therapy (Table 5). Since no other variable significantly influenced acute 
rejection risk and the sample size was small, no multivariable Cox regression analysis was 
conducted. 
 
Pharmacodynamic monitoring of belatacept 
 The pharmacodynamic effect of belatacept was monitored by measuring free CD86 
molecules on circulating monocytes. CD86 was saturated by belatacept at all time points, in both 
rejectors as nonrejectors. Moreover, pretransplantation CD86 molecules/monocyte were not 
predictive for BPAR (HR 0.33, 95%-CI 0.1-2.2). For details about CD86-expression on 
monocytes in belatacept- and tacrolimus-treated patients, refer to SDC, Results and Figure S2, 
SDC, http://links.lww.com/TP/B427.  
 
Discussion 
In this RCT, a belatacept-based and a tacrolimus-based immunosuppressive regimen 
without lymphocyte-depleting induction therapy were compared head-to-head for the first time 
in de novo kidney transplantation. The results of this trial demonstrate that belatacept is not as 
potent as tacrolimus in preventing rejection.  
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In comparison to the 1-year results of the BENEFIT-trial where ciclosporin was used as 
comparator,
7
 we found a more pronounced difference in both BPAR incidence and severity. 
Ninety-one percent of BPAR in the belatacept group was classified as type II (or higher),
28
 while 
in the BENEFIT-trial this was 69%. The use of lymphocyte-depleting therapy to treat rejection 
was comparable: circa 50% of BPAR in the BENEFIT-trial vs. 55% in this study. The incidence 
of graft loss caused by BPAR was higher in this study than in the BENEFIT-trial: 3 of 11 vs. 2 of 
39 rejecting patients, respectively.  
 
This larger difference in rate and severity of BPAR is not explained by dissimilarities 
between study groups. In the present study 1) there were no transplantations with deceased 
donors; 2) there were no patients with a PRA >30%; and 3) the proportion of Caucasians was 
larger. All 3 characteristics are associated with a lower BPAR risk.
29-35
 In contrast, the 
proportion of preemptive transplantations was high in our study (55% of included patients), 
which may have led to the inclusion of patients with a more potent immune system.
36-38
 Another 
explanation for the higher BPAR-rate could be that in this study TDM for MPA was performed, 
whereas this was not the case in the BENEFIT-trial. It is therefore, theoretically possible that 
belatacept-treated patients in BENEFIT were exposed to higher MPA concentrations.
1
 However, 
we feel that this is an unlikely explanation as ciclosporin lowers exposure to MPA, whereas 
tacrolimus does not have such an effect.
39 
 
Our findings are in line with the higher BPAR rates observed in large retrospective 
studies and a small cohort study comparing belatacept to tacrolimus.
13, 14, 18
Wen et al, conducted 
a retrospective cohort study using registry data of a time period of 3 years, and compared 1-year 
clinical outcomes between belatacept- and tacrolimus-treated adult kidney transplant recipients.
39
 
Although the incidence of BPAR was not as high as in the present trial, Wen et al, also observed 
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significantly higher BPAR rates among belatacept-treated patients as compared with tacrolimus-
treated patients who would have been eligible for participation in the BENEFIT-study: 15% of 
patients treated with belatacept and lymphocyte depleting antibody therapy, versus 23% of 
patients treated with belatacept without lymphocyte depleting antibody therapy, versus 6% of 
tacrolimus-treated patients. Nonetheless, it is important to stress that the higher incidence of 
BPAR in the present study should be interpreted with caution, because the study here included 
limited numbers of patients, had limited statistical power and may therefore be a chance finding.   
 
In this study, no suitable pretransplant biomarker was found to predict belatacept-
resistant BPAR.
15, 16, 18, 19
 The first potential biomarker, pretransplant CD8
+
CD28
-
 T cell number, 
seemed a logical choice as these highly cytotoxic cells lack surface CD28 and are therefore not 
susceptible to belatacept.
15-17
 Possible explanations for the observation that these cells were not 
associated with BPAR may be that 1) even though these cells are highly cytotoxic, they lack 
proliferative capacity,
40
 and 2) the CD28-CD80/86 pathway is not the sole mediator of 
belatacept-resistant rejection. Targeting other co-stimulatory pathways, like CD40-40L, 
simultaneously with belatacept, might be more efficient to prevent BPAR.
41, 42
 Preliminary data 
from Cortes-Cerisuelo et al, suggest that not the lack of CD28 on these cells before 
transplantation, but the potential to down-regulate CD28 after donor antigen stimulation is 
associated with BPAR in belatacept-treated patients.
43 
 
 The second biomarker, pretransplant CD4
+
CD57
+
PD1
-
 T cell number, was associated to 
belatacept-resistant rejection in an observational cohort study.
18
 These findings were not 
confirmed here. Apart from differences in study design, the dissimilarities in study populations 
may explain this discrepancy.
23-26
 Our study population 1) was mostly Caucasian; 2) received 
mostly preemptive transplants; and 3) was shorter on dialysis. These factors have, however, not 
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been associated with CD57 expression, and the proportions of CD4
+
CD57
+
PD1
-
 T cells were 
similar pretransplantation. Age and CMV status, which influence these proportions
40, 44-48
, were 
also comparable (data not shown).  
 
The final biomarker, CD8
+
CD28
++
 EMRA T cell number, showed potential to predict 
BPAR under belatacept, even though the group medians did not differ between rejectors and 
nonrejectors. One of the 9 nonrejectors and 4 of the 11 rejectors had high numbers of these cells 
pretransplantation (>35 cells/µL). In-depth analysis of the antigen-specificity of these 
CD8
+
CD28
++
 EMRA T cells in larger studies seems warranted.
49 
 
 Pharmacodynamic drug monitoring in the form of measuring free, non-belatacept bound 
CD86 molecules on circulating monocytes was not useful to predict BPAR under belatacept 
therapy, since free molecules were not higher in rejectors pretransplantation, and followed the 
same dynamics in rejectors as in nonrejectors.  
 
 Limitations of this study are the small sample size and the resulting increased chance of 
type II errors. The increased rejection risk among belatacept-treated patients therefore needs to 
be confirmed in larger RCTs. Ideally, such trials will also include biomarker studies and analyze 
pretransplant donor-specific immunity. Also, research on regulatory T cells would be of interest 
since blockade of CD80/86 leads to anergic T cells,
50
 which consequently may fail to activate 
regulatory T cells via CD28. Studies on antigen-specific biomarkers, such as the IFNγ Elispot 
assay, would also be useful to study in larger, prospective trials.
51, 52 
 
 In conclusion, this small RCT showed that belatacept-based immunosuppressive therapy 
results in a significantly higher rejection-rate and severity compared with standard, tacrolimus-
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based therapy. The biomarker data were not informative as there were no differences in 
pretransplant cellular biomarkers between rejectors and nonrejectors. Belatacept adequately 
blocked the CD28-CD80/86 co-stimulatory pathway in all patients, making insufficient 
saturation an unlikely explanation for this higher rejection risk.  
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Figure legends 
 
Figure 1: Trial flowchart.  
All patients who were included in the study were randomized, underwent transplantation and 
received at least 1 dose of belatacept or tacrolimus. 
CDC, cytotoxicity dependent cross-match; CNI, calcineurin inhibitor; EBV, Epstein Barr Virus; 
HIV, human immunodeficiency virus; HLA, human leukocyte antigen; MGUS, monoclonal 
gammopathy of unknown significance; PRA, panel reactive antibodies 
 
Figure 2: Biopsy-proven acute rejection (BPAR)-free survival.  
The time to first BPAR is depicted for the belatacept (dotted line) and the tacrolimus (solid line) 
group. In the tacrolimus group 1 patient died 294 days after transplantation due to traumatic head 
injury.  
 
Figure 3: Clinical outcomes. 
Each line represents the posttransplant course of the 20 individual belatacept- and 20 individual 
tacrolimus-treated patients (separated by the bold dotted line). Time of BPAR ( ), anti-
rejection therapy (methylprednisolone intravenously [ ] or alemtuzumab subcutaneously [ ]), 
switch to tacrolimus ( ), development of donor-specific anti-human leukocyte antigen (HLA) 
antibodies (DSA) ( ), graft loss ( ) and death ( ) are shown. 
In the belatacept group, n = 1 (5%) patient (no. 15) received methylprednisolone for 
presumed rejection pending the results of a kidney biopsy. Biopsy revealed an alternative 
diagnosis namely ascending urinary tract infection. In 1 other case, methylprednisolone was 
administered for suspected rejection (no. 14). A biopsy was not performed because of a 
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coagulation disorder. In the tacrolimus group, n = 3 (15%) patients received methylprednisolone 
for presumed rejection pending biopsy results. In all 3 cases an alternative diagnosis was made: 
acute tubular necrosis in 2 patients (no. 12 and 14) and an ascending urinary tract infection in 1 
case (no. 16). One belatacept-treated patient (no. 13) was not treated for rejection, because the 
diagnosis of vascular rejection (isolated v-lesion) was only made in retrospect after revision of 
the biopsy. 
 
Figure 4: CD8
+
CD28
-
, CD4
+
CD57
+
PD1
- 
and CD8
+
CD28
++
 EMRA T cells 
pretransplantation.  
CD4
+
 and CD8
+
 T cells were gated from 7-AAD negative CD3
+
 lymphocytes (based on forward 
and sideward scatter) and EMRA T cells were gated as CCR7
-
 and CD45RO
-
 T cells. Typical 
examples are given for nonrejectors and rejectors in the belatacept group for CD8
+
CD28
-
, 
CD4
+
CD57
+
PD1
-
 and CD8
+
CD28
++
 EMRA T cells and their intracellular Granzyme B 
expressions (A). The absolute numbers and percentages of CD8
+
CD28
-
, CD4
+
CD57
+
PD1
-
 and 
CD8
+
CD28
++
 EMRA T cells are presented for nonrejectors and rejectors (B). 
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SUPPLEMENTAL MATERIALS AND METHODS 
 
Detailed additionalMaterials and Methods 
 
Additional (immunosuppressive) treatment – detailed information 
The additional immunosuppressive therapy was identical in both groups and consisted of 
basiliximab (Simulect; Novartis Pharma B.V., Arnhem, the Netherlands) in a dose of 20 mg 
administered intravenously on day 0 (immediately before kidney transplant reperfusion) and day 
4 after transplantation. Patients also received a starting dose of 1000 mg mycophenolate mofetil 
(MMF; CellCept; Roche Pharmaceuticals, Woerden, the Netherlands) twice daily aiming for 
plasma mycophenolic acid (MPA) predose concentrations between 1.5 and 3.0 mg/L. In addition, 
all patients received prednisolone in a dose of 50 mg twice daily intravenously on days 0–3, 
followed by 20 mg orally once daily (on days 4–14), after which the dose was tapered to 5 mg at 
month 3 after transplantation. Patients continued to receive 5 mg of prednisolone for the rest of 
the first posttransplant year. 
All patients received trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis 
Jirovecii pneumonia for at least 3 months. Patients receiving a kidney from a cytomegalovirus 
(CMV)-positive donor and patients who were seropositive for CMV received prophylaxis with 
valganciclovir for a duration of 6 months. 
Additional antirejection therapy consisted of 3 doses of 1000 mg methylprednisolone 
intravenously for 3 consecutive days. In case of glucocorticoid-resistant rejection, lymphocyte-
depleting therapy with 1 dose of 30 mg of alemtuzumab was administered subcutaneously.
1
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Primary end points – BPAR scoring methods 
BPAR was scored as part of routine clinical care by a renal pathologist (M.C.C.) per the 
Banff ’15 classification using 2 µm paraffin sections stained for HE, PAS, Jones and 
immunohistochemistry for C4d on 4 µm sections. After the completion of the study, all biopsies 
were reviewed again in a blinded fashion by 2 pathologists (M.C.C. and J.v.d.T.) per the Banff 
’15 classification.2 In case of discrepancy, biopsies were reviewed and consensus was reached.  
 
Safety 
Data on clinical outcomes and (serious) adverse events [(S)AEs] were collected for safety 
and included patient- and graft survival, estimated GFR (eGFR), proteinuria, and development of 
donor-specific anti-HLA antibodies (DSA). DSA were retrospectively measured in patient sera 1 
day before transplantation, and 1, 6 and 12 months after transplantation. In addition, we 
monitored delayed graft function, malignancies, (opportunistic) infections, posttransplant 
diabetes mellitus (PTDM), neurologic events, and acute tacrolimus-induced nephrotoxicity. 
PTDM was defined as the need for glucose-lowering medical therapy that persisted after month 3 
posttransplantation in a patient not needing such treatment pretransplantation. Acute tacrolimus 
nephrotoxicity was defined as any ≥15% increase of serum creatinine with a return to baseline 
after tacrolimus dose reduction and after exclusion of other causes of renal transplant function 
deterioration. 
Routine laboratory investigations included blood glucose, glycated hemoglobin (HbA1c), 
thrombocytes, leucocytes, hemoglobin (Hb), mean corpuscular volume (MCV), low-density 
lipoproteins (LDL), high-density lipoproteins (HDL) and triglycerides. Blood pressure and body 
weight were measured at every visit to the outpatient clinic.  
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Laboratory Studies – detailed information  
Blood samples were collected on days 0 (pretransplant), 4, 30, 90, and months 6 and 12. 
Serum was collected on days 0, 15, 30, and months 6 and 12. Blood and sera were also collected 
during clinically suspected rejection, before additional antirejection therapy was given. In 
addition, blood and urine samples were collected on a routine basis as part of routine clinical 
care. Proportions of CD8
+
CD28
-
, CD4
+
CD57
+
PD1
-
 and CD8
+
CD28
++
 EMRA T cells were 
determined pretransplantation (1 day before transplantation) and posttransplant (3 months after 
transplantation or during rejection) on thawed isolated peripheral blood mononuclear cells. 
 
Absolute numbers of cells in blood 
 The Becton & Dickinson (BD Biosciences, San José, CA) multi-test 6-color, CD14 FITC 
(Serotec, Kidlington, United Kingdom) and TruCount Tubes were used to measure absolute 
numbers of CD3
+
 T cells, CD4
+
 T-helper cells, CD8
+
 cytotoxic T cells, and CD14
+
 monocytes. 
Absolute numbers were measured in 50 µL blood in the presence of 0.5 mL BD Pharm Lyse. All 
proportions of subsets measured in PBMCs (see below) were calculated back to these absolute 
numbers.  
  
Flow cytometry of cytotoxic T cells in peripheral blood mononuclear cells (PBMCs) 
 Using the Ficoll density method, PBMCs were isolated and stored at -190°C before 
further characterization. T cells were identified by CD3 (AF700, BD), CD4 (V450, BD) and 
CD8a (APC-eF780, eBioscience). The immuno-regulatory receptor PD-1 (PE, BioLegend), the 
cytotoxic marker CD57 (FITC, BD), and the co-stimulatory molecule CD28 (APC, BD) were 
determined on CD4
+
 and CD8
+
 T cells. EMRA CD8
+
 T cells were defined by CD8
+ 
CCR7
-
CD45 
RO
-
, using CCR7 (PE, BD) and CD45RO (PE-Cy7, BD). Intracellular expression of GrB (PE-
CF594, BD) was also assessed.   
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Saturation of CD86 on monocytes and B cells in blood 
The surface expression of free CD86 on CD14
+
 monocytes was assessed using the Lyse-
Wash method per the manufacturer’s instruction. Cells were surface-stained in 100 µL blood and 
erythrocytes were subsequently lysed in 2 mL BD FACS Lysing solution, and washed away 
before measurement. Monoclonal antibodies used were the leukocyte marker CD45 PerCP (BD); 
CD19 PE-Cy7 (BioLegend); CD14 FITC (Serotec); and the for belatacept competitive binder of 
the co-stimulatory molecules of the CD28-pathway, CD86 PE (clone HA5.2B7 Beckman 
Coulter, Brea, CA).
3
 Numbers of CD86 molecules per monocyte were calculated by using 
QuantiBrite beads per manufacturer’s manual (BD).  
 
Detection of serum DSA 
 Using the Luminex single antigen bead assay (Thermo Fisher Scientific, Waltham, MA) 
as previously described,
4
 the development of DSA was determined by measuring the presence of 
DSA against HLA class I and II before and at different set time points after transplantation in 
serum. The MFI cut-off for positivity was 1000. 
 
Panel reactive antibodies 
Sera were tested for HLA-antibody specificities by standard National Institutes of Health 
(NIH) complement-dependent microlymphocytotoxicity test (LCT) using a panel of 54 donors 
yielding a measurement of the PRA (Panel Reactive Antibody). Ifsamples tested positive using a 
Human Linker for Activation of T cell ELISA (LAT) or a Complement-Dependent Cytotoxicity 
Crossmatch(CDC), HLA antibodies were specified with Luminex single antigen test 
(LABScreen SA, One Lambda Inc., Canoga Park, CA, USA). 
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Statistical analyses – additional information 
Patient, graft and biopsy-proven acute rejection (BPAR)-free survival were defined as 1) 
time from transplantation to mortality, 2) time from transplantation to transplant nephrectomy, 
reinitiation of dialysis or (preemptive) retransplantation, and 3) time from transplantation to the 
diagnosis of BPAR, respectively, or as the end of the 12-month follow-up period, whichever 
came earlier.  
In addition to intention-to-treat analyses, on-therapy analyses were conducted and 
included evaluable patients who were still on their assigned regimen 12 months after 
transplantation.  
Categorical variables (+ reference groups) in the univariable Cox regression analyses 
included treatment arm (belatacept vs. tacrolimus), gender (female vs. male), ethnicity 
(noncaucasian vs. Caucasian), HLA mismatches (4 or more vs. less than 4), HLA-DR 
mismatches (2 vs. 1), highest PRA, and CMV serostatus (positive vs. negative).  
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SUPPLEMENTAL RESULTS 
 
On-therapy analysis 
The on-therapy analysis at month 12 revealed that eGFR and protein/creatinine ratios 
were similar between nonrejecting tacrolimus and belatacept-treated patients: median eGFR 57 
(45-89) and 58 (37-84) mL/min per 1.73m
2
, respectively (SDC, Table 3). Graft-loss censored 
median eGFR in belatacept-treated patients that suffered from rejection (n = 7) was 36 (28-76) 
mL/min per 1.73m
2
 at month 12, which was lower than in the nonrejecting belatacept group, p = 
0.001.  
 
Graft function in time in belatacept-treated rejectors 
 The graft function before, during and after BPAR (after additional antirejection therapy) 
is displayed in SDC, Table 4, for the belatacept-group. Before and after BPAR the highest eGFR 
is depicted for each patient. It should be noted 6 patients had a decrease in eGFR after BPAR 
was diagnosed (including 3 graft losses), 2 patients had a similar eGFR after treatment for 
BPAR, and 3 patients had an improved eGFR. 
 
Donor-specific and nondonor-specific anti-HLA antibodies (DSA and non-DSA)  
None of the patients had DSA pretransplantation. During the first posttransplant year, 2 
patients developed DSA, both in the belatacept group (Figure 3 and SDC, Table 5). One month 
after transplantation, patient no. 2 in the belatacept group developed DSA against HLA-DQ2 
(Median Fluorescence Intensity [MFI] 3787; most likely C1q-negative
5
, but these disappeared 
hereafter without additional therapy and no AR occurred. Patient no. 20 in the belatacept group 
developed DSA during her 4th rejection episode (right before losing her graft), which were also 
detectable in the cross match-dependent cytotoxicity test, against HLA-A1 (MFI 18000), B8 
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(MFI 22700), DR3 (MFI 11000), DR52 (MFI 5500) and DQ2 (MFI 16500) (SDC, Table 5). At 
this time, she had already been switched to a tacrolimus-based regimen and had been treated with 
methylprednisolone and alemtuzumab (Figure 3).  
 
Two and 3 patients, in the belatacept and tacrolimus group, respectively, had nondonor 
specific anti-HLA antibodies (non-DSA) pretransplantation. In both the belatacept and the 
tacrolimus group 2 patients developed non-DSA after transplantation (SDC, Table 5).  
 
Pharmacokinetic drug monitoring 
SDC, Table 2 depicts belatacept doses, tacrolimus doses and predose concentrations (C0), 
MMF doses and mycophenolic acid (MPA) C0, and prednisolone doses. MPA C0 were not 
different between the belatacept and tacrolimus groups after 12 months: 2.30 (0.99–3.54) and 
1.83 (0.57–3.67) mg/mL, respectively; p = 0.25. Also, prednisolone doses were similar between 
the belatacept and tacrolimus group in month 12; p = 0.59.  
 
Pharmacodynamic drug monitoring 
The number of belatacept-free CD86 molecules on monocytes was calculated by 
measuring the MFI of bound anti-CD86-PE antibodies. These antibodies bind to CD86 
molecules to the same epitope but with lower affinity than belatacept, which allows for 
measurement of free CD86 molecules.
3
 A typical example is depicted for the MFIs of CD86-PE 
on monocytes for a patient treated with belatacept and a patient treated with tacrolimus (SDC, 
Figure 2A). As evidenced by a linear mixed model, belatacept significantly decreased free CD86 
molecules on monocytes at different time points after transplantation compared to tacrolimus 
(SDC, Figure 2B). Free CD86 molecules/monocyte were 5.9-fold (95%-CI 5.4 to 7.7-fold) 
higher on day 4 and 5.3-fold (95%-CI 4.0 to 7.0-fold) higher 1 month after transplantation in 
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tacrolimus-treated patients compared to belatacept-treated patients, p <0.0001. Hereafter the 
difference in free CD86 molecules/monocyte between the belatacept- and tacrolimus-treated 
patients reduced, because almost half of the belatacept-treated patients had been converted to 
tacrolimus-based therapy. In these patients (n = 8), free CD86 expression returned to baseline 3–
5 months after conversion (SDC, Figure 2C). Pretransplant values for (future) rejectors and 
nonrejectors in the belatacept group were significantly different: 753 (428 – 928) free CD86 
molecules/monocyte versus 882 (528 – 1528) cells/monocyte, respectively, p = 0.04 (SDC, 
Figure 2D). However, the pretransplant values showed a great overlap between rejectors and 
nonrejectors, and the numbers of pretransplant CD86 molecules on monocytes were not 
associated with acute rejection risk (Table 5). No significant differences between (future) 
rejectors and nonrejectors were observed in posttransplant dynamics of free CD86 
molecules/monocyte (SDC, Figure 2E).  
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SUPPLEMENTAL TABLES 
 
SDC, Table 1: Adverse events, intention-to-treat analysis* 
 
Belatacept 
group 
(n = 20) 
Tacrolimus 
group 
(n= 20) 
p 
Blood or lymphatic system 0.75 (0.97) 1.00 (0.92) 0.22 
 Leucopenia 7 7  
 Anemia 6 10  
 Thrombocytopenia 1 1  
 Other 1 2  
Bleeding and thrombotic events 0.30 (0.57) 0.40 (0.60) 0.52 
 Major bleeding 0 2  
 Minor bleeding 4 2  
 Thrombosis 2 4  
Cancer 0 0 - 
Cardiovascular 0.95 (0.83) 1.20 (0.83) 0.33 
 Acute coronary syndrome / 
myocardial ischemia 
1 1  
 Cardiac decompensation / volume 
overload 
2 3  
 Hypertension 12 17  
 Other 4 3  
Gastrointestinal 0.65 (0.67) 0.60 (1.00) 0.40 
 Diarrhea 2 4  
 Other 11 8  
Infection 2.25 (1.86) 1.90 (1.83) 0.46 
 Opportunistic infection 0.45 (0.69) 1.90 (1.83) 0.57 
 BKV 2 1  
 CMV 1 2  
 EBV 1 0  
 HSV 0 1  
 VZV 0 0  
 Fungal 5 2  
 Other infection 1.80 (1.70) 1.60 (1.64) 0.61 
 Urinary tract infection 20 14  
 Upper respiratory tract 
infection 
8 4  
 Pneumonia 2 0  
 Gastrointestinal infection 1 2  
 Other 5 12  
Locomotor system disorder 0.25 (0.55) 0.20 (0.52) 0.70 
Metabolism or nutrition 1.75 (1.16) 2.00 (1.56) 0.84 
 Posttransplant diabetes mellitus 1 7  
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 Hypo- / hyperglycemic 
dysregulation 
4 9  
 Calcium disorder (hypo- / 
hypercalcemia) 
6 3  
 Potassium disorder (hypo- / 
hyperkalemia) 
6 9  
 Hypophosphatemia 6 6  
 Dyslipidemia 8 4  
 Liver enzyme abnormality 3 1  
 Other 1 1  
Nervous system 0.50 (1.00) 0.65 (0.88) 0.36 
 CVA/TIA 1 0  
 Tremor 2 8  
 Headache 1 1  
 Other 6 4  
Skin-related disorders 0.15 (0.37) 0.30 (0.47) 0.26 
Surgical or procedural complication 0.10 (0.31) 0.20 (0.52)  
 Acute tubular necrosis 1 2  
 Delayed graft function 1 1  
 Renal infarction 0 1  
 Other 0 0  
Tacrolimus-induced nephrotoxicity 0.05 (0.22) 0.40 (0.60) - 
Urological complication 0.55 (0.76) 0.60 (0.88) 0.96 
 Hydronephrosis 1 4  
 Urinary leakage 2 1  
 Other 8 7  
Wound-related problem 0.15 (0.37) 0.25 (0.44) 0.44 
 Wound infection 2 3  
 Other 1 2  
Other 1.80 (1.44) 2.20 (2.04) 0.63 
Total 10.25 (4.18) 11.90 (5.43) 0.41 
 
* Meannumber of adverse events (+standard deviation) per patient are depicted for both 
treatment groups for the different categories of adverse events. Numbers of adverse events per 
subcategory are depicted per treatment group. 
BKV, BK virus; CMV, cytomegalovirus; CVA, cerebrovascular accident; EBV, Epstein-Barr 
virus; HSV, herpes simplex virus; N/A, not applicable; VZV, varicella zoster virus; TIA, 
transient ischemic attack. 
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SDC, Table 2: Clinical outcomes, intention-to-treat analysis* 
 
  Belatacept group (n = 20) Tacrolimus group (n = 20)  
  n M3 n M6 n M12 n M3 n M6 n M12 p
†
 
Blood pressure 
            
 
 Systolic / diastolic 
(mmHg) 
1
18 
137 (98 - 
167) / 83 
(40 - 94) 
17 
138 (93 - 
181) / 80 
(50 - 
109) 
17 
147 (106 
- 165) / 
81 (50 - 
85) 
20 
144 (108 – 
178) / 85 
(59 – 98) 
20 
138 (96 – 
184) / 84 
(55 – 95) 
19 
145 (110 
– 170) / 
85 (45 – 
97) 
0.64 
/ 
0.42 
Kidney function 
 
 
 
 
 
 
 
 
 
 
 
  
 Creatinine (µmol/L) 
1
18 
127 (73 – 
276) 
17 
114 (74 
– 219) 
17 
128 (71 
– 207) 
20 
122 (64 – 
242) 
20 
126 (61 – 
179) 
19 
126 (79 
– 179) 
0.80 
 eGFR (mL/min) 
1
18 
52 ( 8 – 
72) 
17 
62 (26 – 
88) 
17 
54 (28 – 
89) 
20 
50 (23 – 
80) 
20 
53 (33 – 
85) 
19 
50 (33 – 
84) 
0.57 
 Protein/Creatinine 
ratio (mg/mmoL) 
1
18 
19.3 (5.2 
– 443.2) 
17 
18.2 (5.8 
– 87.7) 
17 
13.2 (5.7 
– 343.8) 
20 
15.3 (7.3 – 
115.0) 
20 
12.1 (4.2 – 
209.6) 
19 
9.0 (5.3 
– 43.5) 
0.44 
Glucose metabolism 
 
 
 
 
 
 
 
 
 
 
 
  
 Glucose (mmol/L) 18 
5.6 (4.7 – 
9.4) 
17 
5.5 (2.9 
– 13.7) 
17 
5.6 (2.9 
– 13.7) 
20 
6.2 (3.7 – 
10.7) 
20 
6.6 (4.7 – 
13.5) 
19 
6.1 (4.3 
– 26.7) 
0.06 
 HbA1c (mmol/mol) 
6
6 
36 (29 – 
74) 
3 
37 (33 – 
50) 
5 
41 (33 – 
49) 
6 
48 (37 – 
67) 
5 
42 (30 – 
73) 
10 
46 (33 – 
75) 
0.31 
Lipids 
 
 
 
 
 
 
 
 
 
 
 
  
 Cholesterol total 
(mmol/L) 
1
18 
4.6 (2.9 – 
7.5) 
16 
4.7 (3.0 
– 6.9) 
16 
4.7 (3.4 
– 7.2) 
20 
4.5 (2.9 – 
6.5) 
20 
4.5 (3.2 – 
5.9) 
19 
4.7 (3.1 
– 6.9) 
0.55 
 Triglycerides 
(mmol/L) 
1
18 
2.1 ( .1 – 
4.1) 
16 
1.9 (1.1 
– 4.0) 
16 
2.2 (1.2 
– 3.2) 
20 
2.0 (0.8 – 
5.3) 
20 
1.8 (0.7 – 
4.2) 
19 
1.6 (0.9 
– 5.9) 
0.13 
 HDL-cholesterol 
(mmol/L) 
1
18 
1.1 (0.7 – 
3.0) 
16 
1.2 (0.9 
– 3.1) 
16 
1.2 (0.8 
– 3.5) 
20 
1.3 (0.8 – 
2.7) 
20 
1.2 (0.6 – 
2.8) 
19 
1.4 (0.8 
– 3.4) 
0.66 
 LDL-cholesterol 
(mmol/L) 
1
18 
3.0 ( .2 – 
5.3) 
16 
2.8 (1.0 
– 4.9) 
16 
2.8 (1.3 
– 5.3) 
20 
2.4 (1.2 – 
4.4) 
20 
2.6 (1.2 – 
4.3) 
19 
2.7 (1.2 
– 4.3) 
0.30 
Hematology 
 
 
 
 
 
 
 
 
 
 
 
  AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
45 
 
 Hemoglobin 
(mmol/L) 
1
18 
7.2 (5.0 – 
9.5) 
17 
7.6 (6.3 
– 9.6) 
17 
8.2 (7.0 
– 9.9) 
20 
7.5 (6.5 – 
9.4) 
20 
7.7 (6.2 – 
10.5) 
19 
8.4 (6.5 
– 10.5) 
0.85 
 MCV (fL) 18 
96 (89 – 
100) 
17 
93 (88 – 
98) 
17 
92 (83 – 
97) 
20 
94 (69 – 
106) 
20 
90 (68 – 
102) 
19 
88 (72 – 
108) 
0.20 
 Thrombocytes 
(×10^9/L) 
1
17 
222 (162 
– 401) 
17 
232 (119 
– 477) 
17 
214 (138 
– 394) 
20 
231 (148 – 
495) 
20 
235 (131 – 
457) 
19 
245 (163 
– 380) 
0.21 
 Leucocytes 
(×10^9/L) 
1
18 
6.3 ( .0 – 
15.5) 
17 
6.9 (1.9 
– 11.1) 
17 
6.4 (2.2 
– 17.4) 
20 
5.9 (1.3 – 
11.8) 
20 
7.4 (1.7 – 
14.2) 
19 
8.4 (4.0 
– 12.0) 
0.12 
Pharmacokinetics 
 
 
 
 
 
 
     
  
 Belatacept dose (mg) 
1
16 
800 (575 
– 938) 
11 
400 (300 
– 45) 
10 
381 (300 
– 450) 
- N/A - N/A - N/A N/A 
 Tacrolimus dose (mg) 
2
2 
10.0 (10.0 
– 10.0) 
6 
5.5 (3.5 
– 10.0) 
7 
5.0 (3.0 
– 8.0) 
20 
4.0 (2.0 – 
8.0) 
20 
4.0 (2.0 – 
6.0) 
19 
4.0 (2.5 
– 7.0) 
0.19 
 Tacrolimus 
concentration (ug/L) 
2
2 
2.2 (1.5 – 
5.5) 
6 
5.8 (4.2 
– 8.3) 
7 
7.2 (4.5 
– 8.6) 
20 
7.0 (4.1 – 
10.7) 
20 
6.3 (2.6 – 
9.9) 
19 
6.8 (4.4 
– 13.3) 
0.53 
 Mycophenolate 
mofetil dose (mg) 
1
18 
1000 (500 
– 2000) 
17 
1000 
(500 – 
2000) 
17 
1000 
(500 – 
2000) 
20 
1000 (500 
– 2000) 
19 
1000 (0 – 
2000) 
18 
1000 (0 
– 2000) 
0.47 
 Mycophenolate acid 
concentration 
(mg/mL) 
1
17 
3.04 
(0.52-
10.00) 
16 
2.45 
(0.98 – 
5.21) 
17 
2.30 
(0.99 – 
3.54) 
20 
2.53 (1.03 
– 10.00) 
19 
1.69 (0.96 
– 4.24) 
18 
1.83 
(0.57 – 
3.67) 
0.25 
 Prednisone dose (mg) 
1
18 
5.0 (5.0 – 
10.0) 
17 
5.0 (5.0 
– 10.0) 
17 
5.0 (5.0 
– 10.0) 
20 
5.0 (5.0 – 
10.0) 
20 
5.0 (5.0 – 
10.0) 
19 
5.0 (2.5 
– 10.0) 
0.59 
 
* Censored for graft loss and death; 
†
 Comparison between patients from the belatacept group and the tacrolimus group 12 months 
after transplantation 
Target tacrolimus C0 of 5 – 10 ng/mL were achieved in 75%, 85% and 95% of patients in the tacrolimus group 3, 6 and 12 months 
after transplantation, respectively. Target MPA C0 of 1.5 – 3.0 mg/mL were achieved in 45%, 40% and 40% of patients in the 
tacrolimus group respectively 3, 6 and 12 months after transplantation, and in 30%, 40% and 60% of patients in the belatacept group 
respectively 3, 6 and 12 months after transplantation. AC
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Data present medians (plus ranges).  
BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high density lipoproteins; LDL, low density lipoproteins; 
M3, 3 months after transplantation; M6, 6 months after transplantation, M12, 12 months after transplantation; MCV, mean corpuscular 
volume
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SDC, Table 3: Graft function 12 months after transplantation 
 Belatacept 
nonrejectors 
(n=9) 
Belatacept 
rejectors, 
censored for 
graft loss 
(n=8) 
Belatacept 
rejectors, 
including graft 
loss (n=11) 
Tacrolimus 
(n=19) 
Tacrolimus 
nonrejectors 
(n=17) 
Creatinine (µmol/L) 
106 
(71-143) 
163 
(93-207) 
- 
126 
(79-179) 
119 
(79-178) 
eGFR (mL/min) 
57 
(45-89) 
36 
(28-76) 
34 
(0-76) 
50 
(33-84) 
58 
(37-84) 
Protein/Creatinine 
ratio 
11.4 
(7.9-25.0) 
12.2 
(5.7-343.8) 
- 
9.0  
(5.3-43.5) 
9.0 
(5.3-43.5) 
 
Data are medians (plus ranges). Graft function was compared between 1) the belatacept-
treatedrejectors and belatacept-treated nonrejectors and 2) the tacrolimus-treated and belatacept-
treated nonrejectors, using the Mann-Whitney U test. Creatinine concentrationat month 12 was 
significantly higher and eGFR at month 12 was consequently significantly lower in belatacept-
treated rejectors than in belatacept-treated nonrejectors, both p=0.001. These parameters did not 
differ between nonrejecting belatacept-treated and tacrolimus-treated patients at month 12. 
In the group of “Belatacept rejectors, including graft loss” the 3 patients that lost their grafts 
were set to an eGFR of zero on month 12. Creatinine and Protein/Creatinine ratio were not 
calculated for this group, since these could not be determined for the 3 patients after graft loss.  
eGFR, estimated glomerular filtration rate 
 
 
 
 
 
 
 
  
AC
CE
PT
ED
Copyright © Wolters Kluwer Health. Unauthorized reproduction of this article is prohibited.
48 
 
SDC, Table 4: Response to antirejection therapy in belatacept-treated rejectors 
  Creatinine eGFR 
No. 
(Patient) 
Best 
before BPAR 
Best 
after 
Best 
before BPAR Best after 
3 84 132 93 59 35 52 
5 89 698 N/A 56 5 0 
6 155 211 136 39 27 45 
7 148 188 164 45 34 40 
13 89 107 93 80 65 76 
14 109 148 110 72 50 71 
15 227 279 145 25 19 41 
16 106 210 152 62 28 41 
17 305 807 N/A 14 5 0 
19 325 367 161 18 16 41 
20 162 175 N/A 33 30 0 
 
Patient numbers are the same depicted as in Figure 3. For detailed clinical course per patient, 
please refer to this figure. Creatinine and estimated glomerular filtration rates (eGFR) are given 
for the 10 belatacept-treated rejectors before, during and after rejection (when applicable, before 
second rejection episodes). Both before and after rejection the highestmeasuredeGFRs are 
depicted. Patients no. 6, 16 and 19 were switched to tacrolimus (almost) immediately after 
rejection occurred. Patients no. 5 lost her graft immediately after rejection, and patients no. 17 
and 20 were switched to tacrolimus, but still lost their grafts thereafter (eGFRs after rejection 
were set to zero). Patients no.7, 14 and 15 were switched to tacrolimus after a second episode of 
acute rejection. Patient no. 13 was diagnosed with BPAR after revision of the biopsy, and was 
therefore not treated with additional antirejection therapy. This patient had an isolated v-lesion 
which may explain the excellent outcome despite no treatment. Finally, patient no. 3 was 
switched after his third rejection episode.     
N/A, not applicable 
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SDC, Table 5: Anti-HLA antibodies in serum 
 Belatacept group 
(n = 20) 
Tacrolimusgroup 
(n = 20) 
p 
Donor-specific 
Preexistent - - - 
De novo 
2 (10%) 
[Patients no. 2 and 
20] 
- 0.49 
Nondonor-
specific 
Preexistent 
2 (10%) 
[Patients no. 2 and 
12] 
3 (15%) 
[Patients no. 3, 11 
and 12] 
1.00 
De novo 
2 (10%) 
[Patients no. 7 and 
20] 
2 (10%) 
[Patients no. 6 and 
20] 
1.00 
 
Patient numbers are the same as in Figure 3. None of the patients had donor-specific 
antihuman leukocyte antigen (HLA) antibodies (DSA) pretransplantation. During the first 
posttransplant year, 2 patients developed DSA, both in the belatacept group. Patient no. 2 in the 
belatacept group developed DSA against HLA-DQ2 (MFI 3787) 1 month after transplantation, 
but this disappeared hereafter without additional therapy and no acute rejection occurred. Patient 
no. 20 in the belatacept group had DSA, which were also detectable in the cross match-
dependent cytotoxicity test, against HLA-A1 (MFI 18,000), -B8 (MFI 22700), -DR3 (MFI 
11000), -DR52 (MFI 5500) and -DQ2 (MFI 16500) during her 4th rejection episode right before 
losing her graft. Now, she was already switched to a tacrolimus-based regimen and had been 
treated with multiple methylprednisolone and alemtuzumab gifts (Figure 3).  
Two and 3 patients, in the belatacept and tacrolimus group, respectively, had nondonor-
specific anti-HLA antibodies (non-DSA) pretransplantation. Patient no. 2 in the belatacept group 
had non-DSA against DR1 that remained present after transplantation, without clinical 
consequences. Patient no. 12 in the belatacept group had non-DSA against HLA-Dp11 which 
disappeared after transplantation. No rejection occurred. Patients no. 3, 11 and 12 in the 
tacrolimus group had non-DSA pretransplantation against HLA-B76, -DP1, and -DP; -DR4; and 
-B15; respectively. Only patient no. 3 suffered from an acute rejection Banff type 2B. No serum 
was available from this patient at the time of rejection, but in sera from month 1 to 12 no non-
DSA were detected. Also in the other 3 patients, preexistent anti-HLA antibodies disappeared 
after transplantation. 
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Two patients in the belatacept group (no. 7 and no. 20) developed non-DSA. Patient no. 7 
in the belatacept group developed non-DSA against HLA-DQ3 (measured on day 30) before he 
was diagnosed with an acute Banff type 2B rejection 44 days after transplantation. These non-
DSA were also positive during rejection. After treatment with methylprednisolone they were no 
longer detectable and remained so throughout follow-up. Patient no. 20 in the belatacept group 
developed non-DSA against HLA-A24, -A68, and -DQ3 simultaneously with DSA. Two patients 
in the tacrolimus group (no. 6 and no. 20) developed non-DSA, without clinical consequences in 
the first year after transplantation against HLA-DP14 and HLA-A24, respectively.  
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SDC, Table 6: Baseline characteristics of (future) rejectors and nonrejectors in the belatacept 
group  
 
Belatacept (n= 20) 
p rejectors 
(n= 11) 
nonrejectors 
(n= 9) 
Age at transplantation (years) 47 (25-76) 60 (40-74) 0.41 
Male / female  7 (64%) / 4 (36%) 7 (78%) / 2 (22%) 0.49 
Ethnicity    0.07 
 Caucasian 11 (100%) 6 (67%)  
 African - 2 (22%)  
 Asian - 1 (11%)  
Body weight (kg) 83.3 (63.5 - 111.4) 76.0 (56.6 - 98.6) 0.26 
HLA A mismatch (mean ± SD) 1.0 (± 0.6) 1.1 (± 0.8) 0.84 
HLA B mismatch (mean ± SD) 1.4 (± 0.5) 1.2 (± 0.4) 0.63 
HLA DR mismatch (mean ± SD) 1.2 (± 0.4) 1.0 (± 0.5) 1.00 
Current PRA (%) 0 (0 - 4) 0 (0 - 5) 0.55 
Peak PRA (%) 4 (0 - 6) 4 (0 - 5) 0.37 
CMV status at transplantation    0.37 
 Donor + / Recipient - 1 (9%) 2 (22%)  
 Donor + / Recipient + 2 (18%) 2 (22%)  
 Donor - / Recipient - 6 (55%) 1 (11%)  
 Donor - / Recipient + 2 (18%) 4 (44%)  
Donor age at transplantation (years) 60 (43 - 69) 53 (24 – 71) 0.33 
Related / unrelated donor  4 (36%) / 7 (64%) 2 (22%) / 7 (78%) 0.64 
Cause of end-stage renal disease    0.90 
 Diabetes mellitus 1 (9%) 2 (22%)  
 Hypertension - 2 (22%)  
 IgA nephropathy - 1 (11%)  
 Polycystic kidney disease 2 (18%) 1 (11%)  
 Obstructive nephropathy 2 (18%) 1 (11%)  
 Unknown 3 (27%) 2 (22%)  
 Other 3 (27%) 0 (0%)  
Renal replacement therapy    0.37 
 None (preemptive) 7 (64%) 3 (33%)  
 Hemodialysis 3 (27%) 4 (44%)  
 Peritoneal dialysis 1 (9%) 2 (22%)  
Time on dialysis therapy (days) 560 (147-2633) 425 (123-2782) 1.00 
Number of kidney transplantation   1.00 
 First 10 (91%) 9 (100%)  
 Second 1 (9%) -  
Continuous variables are presented as medians (plus ranges) and categorical variables as 
numbers (plus percentages), unless otherwise specified 
BPAR, biopsy-proven acute rejection; CMV, cytomegalovirus; HLA, human leukocyte antigen; 
PRA, panel reactive antibodies; SD, standard deviation. 
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SUPPLEMENTAL FIGURES 
 
SDC, Figure 1. CD8+CD28-, CD4+CD57+PD1- and CD8+CD28++ EMRA T cells during rejection or 3 
months after transplantation. CD4+ and CD8+ T cells were gated from 7-AAD negative CD3+ lymphocytes 
(based on forward and sideward scatter) and EMRA T cells were gated as CCR7- and CD45RO- T cells (See 
Figure 4). The absolute numbers and percentages of CD8+CD28-, CD4+CD57+PD1- and CD8+CD28++ EMRA 
T cells are presented for nonrejectors 3 months after transplantation and for rejectors during acute rejection before 
additional antirejection therapy was given. 
 
N.B.: From 1 rejector no materials were obtained during rejection, because biopsy-proven acute rejection was 
diagnosed in retrospect after revision by a second pathologist. 
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SDC, Figure 2. Pharmacodynamic drug monitoring of belatacept. 
The median fluorescence intensity (MFI) of CD86 was assessed on circulating monocytes in 
belatacept and tacrolimus-treated patients using a competitive monoclonal antibody (clone 
HA5.2B7, solid line) with an IgG control (dotted line) (A). Free CD86 molecules per monocyte 
were calculated from MFIs (medians + interquartile ranges) and compared between the 
belatacept (triangles) and tacrolimus (squares) group on different time points in an intention-to-
treat analysis using a linear mixed model (B). Free CD86 molecules/monocyte in tacrolimus-
treated patients compared to belatacept-treated patients were 5.9-fold (95% CI 4.5 to 7.7-fold) 
higher on day 4; 5.3-fold (95% CI 4.0 to 7.0-fold) higher on month 1; 3.7-fold (95% CI 2.8 to 
4.8-fold) higher on month 3; 2.6-fold (95% CI 2.0 to 3.4-fold) higher on month 6; and 2.1-fold 
(95% CI 1.6 to 2.8-fold) on month 12. Free CD86 molecules/monocytes were measured in n = 8 
patients which were converted to a tacrolimus-based therapy after acute belatacept-resistant 
rejection (C). Numbers of free CD86 molecules/monocytes pretransplantation were compared 
between nonrejectors (n = 9) and rejectors (n = 11) in the belatacept group (D), as well as CD86 
molecules/monocyte on day 4 and month 3 or during rejection after transplantation (E). 
AR, acute rejection; D-1, 1 day pretransplantation; D4, 4 days after transplantation; M1, 1 month 
after transplantation; M3, 3 months after transplantation; M6, 6, 
 months after transplantation; M12, twelve months after transplantation; MMF, mycophenolate 
mofetil  
* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001 
N.B.: In (D) black lines represent the medians; the upper and lower border of the boxes represent 
the 25th and 75
th
 percentiles; the error lines represent 10th and 90th percentiles. 
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